相关临床试验
102
9 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1903
进行中（未招募）
7
6.9%
已完成
73
71.6%
尚未招募
2
2.0%
招募中
11
10.8%
终止
5
4.9%
Unknown
2
2.0%
撤回
2
2.0%
暂无批准数据
- A 23-year-old reticulated python at Chester Zoo became the first snake in the world to receive electrochemotherapy, a cancer treatment normally used in humans. - The python, named Jodie Foster, was diagnosed with a fibrosarcoma in her jaw that returned after surgery and began destroying her jawbone. - The 90-minute procedure combined surgical removal of the tumour with electrochemotherapy using the cancer drug bleomycin to target remaining cancerous cells. - Months after treatment, the snake is eating normally and a final check confirmed no signs of the cancer returning, with details to be formally published for the veterinary community.
- Neuroblastoma, the most common extracranial solid tumor in children under five, accounts for approximately 15% of pediatric cancer deaths, with five-year survival below 60% for high-risk cases. - A narrative review published in the World Journal of Pediatric Surgery synthesizes current evidence on risk-adapted diagnosis, treatment sequencing, and long-term survivorship care. - The International Neuroblastoma Risk Group Staging System (INRGSS) and molecular markers such as MYCN amplification guide treatment intensity, ranging from observation alone to multimodal therapy. - For carefully selected infants monitored without immediate intervention, a prospective study reported 10-year event-free survival of 94.7% and overall survival of 97.4%.
- A Nature Immunology study led by La Jolla Institute for Immunology and University of Liverpool provides the first comprehensive look at tissue-resident memory T cells (TRM cells) in human lungs. - Researchers analyzed more than 87,000 lung TRM cells from 40 participants and found these cells can target viruses, bacteria, and even deadly fungal pathogens. - Human lung TRM cells persist for months or years, unlike mouse TRM cells, which undergo quick attrition, underscoring the value of studying human immune cells directly. - The findings suggest vaccine researchers may need to examine lung T cells, not just blood samples, to develop longer-lasting immunity against severe respiratory infections.
- A multinational analysis of 27,252 children found that at least one rotavirus vaccine dose reduced rotavirus-positive gastroenteritis mortality by approximately 75.8% (95% CI, 28.4–91.8). - The vaccine's effect against all-cause acute gastroenteritis mortality was smaller and not statistically significant, at about 20.8% (95% CI, −47.0 to 57.3). - Children in rural hospitals and African countries faced disproportionate risk, with rural children nearly twice as likely to have received no vaccine doses compared with urban peers. - Investigators emphasize timely on-schedule vaccination, while experts call for birth-dose strategies, injectable alternatives, and sustained investment in nutrition and health infrastructure.
- Analysis of 5.8 billion medications dispensed to 52.6 million people in England from 2019–2024 reveals a sharp deprivation gap, with nearly twice as many medicines dispensed to the most deprived groups by age 40. - Polypharmacy is rising steadily, with over 40% of 70-year-olds dispensed five or more medications and 5% of three-year-olds receiving three or more medicines. - Post-pandemic recovery in drug initiation was observed for cardiovascular and diabetes medications, while dispensing for mental health and gastrointestinal conditions remained below pre-pandemic levels. - The research team calls for permanent linked medicines data infrastructure to enable real-time pharmacovigilance, guideline development, and equitable prescribing across the NHS.
- Adults with both epilepsy and hearing loss who use hearing aids had a 23% lower risk of developing dementia compared to non-users, according to research presented at EAN Congress 2026. - The absolute risk reduction was 2.7 percentage points over five years, equating to one fewer dementia case for every 37 people using hearing aids. - No significant association was found between hearing aid use and dementia risk in the overall hearing-loss population or among people with stroke, migraine, type 2 diabetes, chronic kidney disease, heart failure, or osteoarthritis. - Researchers suggest reduced cognitive reserve in epilepsy patients may explain why removing the strain of hearing impairment has a greater impact in this population.
- The University of Liverpool has formed a strategic partnership with Boston-based BPGbio, Inc. to enhance AI-powered drug discovery through the NAi® Bayesian AI platform. - The collaboration will analyze large-scale healthcare data including medical scans, lab results, and multi-omics data to identify causal disease mechanisms and potential drug targets. - BPGbio's NAi® platform has already contributed to drug target discovery in oncology, mitochondrial disease, and neurology, with this partnership aimed at advancing single-cell level analysis capabilities. - The initiative, conducted through Liverpool's Civic HealthTech Innovation Zone, represents a significant investment in precision medicine and will create regional jobs while strengthening the UK's position in global health technology.
- University of Liverpool researchers found that diabetic patients over 55 taking metformin were 37% less likely to develop intermediate age-related macular degeneration over five years compared to those not taking the drug. - The study analyzed retinal photographs from 2,545 people in Liverpool's diabetic eye screening program, representing the first research to grade AMD severity directly from eye images rather than relying on diagnostic codes. - With no current treatment available for geographic atrophy and expensive injection therapies for wet AMD, metformin could offer an accessible treatment option for a condition affecting 1.1-1.8 million people in the UK. - Researchers emphasize the need for clinical trials to test metformin as a dedicated AMD treatment, as the current findings only apply to diabetic patients and show no effect on early AMD stages.
- Medicines for Malaria Venture (MMV), the world's leading antimalarial product development partnership, has joined the Infection Innovation Consortium (iiCON) as a core partner to accelerate infectious disease research. - The collaboration will integrate MMV's AI/machine learning drug design tools and global screening networks with iiCON's platforms for natural product screening, antimicrobial resistance research, and organoid-based drug discovery. - iiCON has secured over £251 million in investment since 2020 and has supported 36 new products to market, with over 5 billion units of life-saving treatments reaching global communities. - The partnership aims to leverage synergies between MMV's antimalarial expertise and iiCON's broader infectious disease platforms to develop new antibiotics, antivirals, antiparasitics, and antifungals.
- The University of Liverpool and CyanoCapture Ltd have formed a 12-month research partnership to develop next-generation carboxysome-based targeted drug delivery systems using engineered cyanobacteria. - The collaboration combines Professor Luning Liu's breakthrough research on protein nanocages with CyanoCapture's proprietary genetic engineering tools and scalable cyanobacteria strains capable of manufacturing peptide molecules from CO2. - The partnership aims to address off-target effects in drug development by creating affordable protein nanocages that can load peptides to target specific tissues, potentially solving clinical trial failures. - CyanoCapture has successfully scaled cultivation to 3,400 litres with record-breaking productivities and plans to transfer processes to CDMO facilities in India and Canada by 2026.
